Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 May 2016
Price : $35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2015 Planned number of patients changed from 50 to 70 as reported by University Hospital Medical Information Network - Japan.
- 19 Mar 2014 Status changed from not yet recruiting to recruiting University Hospital Medical Information Network - Japan.